2026-04-17T03:50:48Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1985252025-12-05T09:22:14Zcom_2072_1057col_2072_478799col_2072_478917
RECERCAT
author
Veeck, Jürgen
author
Ropero, Santiago
author
Setién, Fernando
author
Gonzalez-Suarez, Eva
author
Osorio, Ana
author
Benitez, Javier
author
Herman, James G.
author
Esteller, Manel
2023-05-26T13:20:03Z2023-05-26T13:20:03Z2010-10-102023-05-26T13:20:03Z
Recently, Fong et al reported the antitumor activity of the poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitor olaparib (AZD2281; KU-0059436) in patients with BRCA1/BRCA2 germline mutated ovarian cancer. Female BRCA1 and BRCA2 mutation carriers have a significantly elevated lifetime risk of breast and ovarian cancer. BRCA1 and BRCA2 proteins play major roles in DNA double-strand break repair through homologous recombination, and inhibition of DNA single-strand break repair leads to the accumulation of double-strand breaks. These potentially lethal events in homologous recombination-deficient cells could be exploited for therapeutic purposes. The PARP-1 protein is essential for single-strand break repair, and inhibition of PARP leads to persistence of DNA lesions normally repaired by homologous recombination.
(c) American Society of Clinical Oncology, 2010 info:eu-repo/semantics/openAccess
Proteïnes supressores de tumors
ADN
Malalties de l'ovari
Genètica
Tumor suppressor protein
DNA
Ovary diseases
Genetics
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitorsBRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion